RESULTS	However , analysis based on stage showed that a preoperative intratumoral injection of OK-432 significantly improved the 5-year survival rate of patients with Stage III cancer ( P = 0.0229 ) , at 47.7 % for the OK-432 group and 27.5 % for the control group .\